VIROLOGIC AND IMMUNOLOGIC EFFECTS OF ADDING ABACAVIR TO HIV PATIENTS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。确定阿巴卡韦的加入是否减少了使用因地那韦和依非韦伦抑制病毒的受试者的病毒复制。估计加入阿巴卡韦后游离病毒的衰变率。在一组持续病毒抑制4年的患者中描述HIV免疫反应。确定在阿巴卡韦增强抗逆转录病毒治疗时是否观察到增强和/或增强的HIV免疫反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine if the addition of abacavir decreases viral replication in subjects with viral suppression achieved with indinavir and efavirenz. Estimate the decay rate of free virus after the addition of abacavir. Characterize HIV immune responses in a cohort of patients with sustained viral suppression for 4 years. Determine if increased and/or amplified HIV immune responses are observed when antiretroviral therapy is augmented with abacavir.